INZY News and Press, Inozyme Pharma Inc. From 07/26/22

BOSTON, July 26, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced that it has entered into a debt financing facility for up to...

Gainers: Direct Digital Holdings ( DRCT ) +81% . ToughBuilt Industries ( TBLT ) +54% . Stronghold Digital Mining ( SDIG ) +42% . Calithera Biosciences ( CALA ) +27% . CorMedix ( CRMD ) +23% . Allakos ( ALLK ) +22% ...

Data from a handful of patients in the phase 1 portion of a phase 1/2 trial showed that Inozyme Pharma's ( NASDAQ: INZY ) INZ-701 led to positive biomarker, safety, and pharmacokinetic results in adults with ABCC6 Deficiency . All three adults showed rapid and signific...

- Rapid and significant increase in plasma pyrophosphate (PPi) levels observed in all three subjects in lowest dose cohort (0.2 mg/kg) – - INZ-701 was generally well-tolerated and exhibited a favorable initial safety profile – - First evidence that INZ-701 ...

Inozyme Pharma (NASDAQ:INZY) will work with the Rady Children’s Institute for Genomic Medicine to evaluate a novel newborn screening technology that can help diagnose genetic diseases. Rady has BeginNGS, a precision medicine tool that involves rapid Whole Genome Sequencing to scre...

BOSTON, June 16, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced a partnership with Rady Children’s Institute for Geno...

Inozyme Pharma (NASDAQ:INZY) appoints Kurt Gunter, M.D., as chief medical officer.  Dr. Gunter, who most recently served as chief medical officer, cell therapy, and head of regulatory affairs at Athenex. “Kurt’s experience across the entirety of the drug development process...

BOSTON, June 07, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced the appointment of Kurt Gunter, M.D., as chief medical offic...

BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced Axel Bolte, MSc, MBA, the company’s co-founder, president...

Jefferies has initiated Inozyme (INZY) at hold saying proof-of-concept data on lead asset INZ-701 for two rare abnormal mineralization disorders. The firm has a $5 price target (~25% upside based on Wednesday's closing price). For further details see: Inozyme initiated at hold at Jeffer...